Cayston (aztreonam)
- Region
- 🇪🇺 EU
- Active substance
- aztreonam
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- Cystic Fibrosis; Respiratory Tract Infections
- EU approval
- Mon 21 Sep 2009
- Application
- EMEA/H/C/000996
- ATC
- J01DF01
- Official record
- www.ema.europa.eu
Indication
Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Emblaveo Authorised · Pfizer Europe MA EEIG
Follow Cayston
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.